Development of novel IVD assays: a manufacturer's perspective.
IVD manufacturers are heavily reliant on novel IVD assays to fuel their growth and drive innovation within the industry. They represent a key part of the IVD industry's value proposition to customers and the healthcare industry in general, driving product differentiation, helping to create demand for new systems and generating incremental revenue. However, the discovery of novel biomarkers and their qualification for a specific clinical purpose is a high risk undertaking and the large, risky investments associated with doing this on a large scale are incompatible with IVD manufacturer's business models. This article describes the sources of novel IVD assays, the processes for discovering and qualifying novel assays and the reliance of IVD manufacturers on collaborations and in-licensing to source new IVD assays for their platforms.
Metcalfe
Thomas A
TA
Translational Research Sciences, F. Hoffmann-La Roche AG Basel, Switzerland. thomas.metcalfe@roche.com
D015415:Biomarkers; D001709:Biotechnology / Q000379:methods / Q000639:trends*; D019411:Clinical Laboratory Techniques / Q000379:methods / Q000639:trends*; D003132:Commerce / Q000379:methods / Q000639:trends; D019295:Computational Biology / Q000379:methods / Q000639:trends; D055808:Drug Discovery / Q000379:methods / Q000639:trends; D004345:Drug Industry / Q000379:methods / Q000639:trends*; D005820:Genetic Testing / Q000379:methods / Q000639:trends; D006801:Humans; D011933:Reagent Kits, Diagnostic / Q000639:trends*
D015415:Biomarkers; D011933:Reagent Kits, Diagnostic